Literature DB >> 33535434

The Topical Nanodelivery of Vismodegib Enhances Its Skin Penetration and Performance In Vitro While Reducing Its Toxicity In Vivo.

Maria Natalia Calienni1,2,3, Daniela Maza Vega1,2, C Facundo Temprana4,5, María Cecilia Izquierdo1,2, David E Ybarra1,2, Ezequiel Bernabeu5,6, Marcela Moretton5,6, Fernando C Alvira1,2, Diego Chiappetta5,6, Silvia Del Valle Alonso1,2, María Jimena Prieto1,2, Jorge Montanari1,2,3.   

Abstract

Vismodegib is a first-in-class inhibitor for advanced basal cell carcinoma treatment. Its daily oral doses present a high distribution volume and several side effects. We evaluated its skin penetration loaded in diverse nanosystems as potential strategies to reduce side effects and drug quantities. Ultradeformable liposomes, ethosomes, colloidal liquid crystals, and dendrimers were able to transport Vismodegib to deep skin layers, while polymeric micelles failed at this. As lipidic systems were the most effective, we assessed the in vitro and in vivo toxicity of Vismodegib-loaded ultradeformable liposomes, apoptosis, and cellular uptake. Vismodegib emerges as a versatile drug that can be loaded in several delivery systems for topical application. These findings may be also useful for the consideration of topical delivery of other drugs with a low water solubility.

Entities:  

Keywords:  cellular uptake; cytotoxicity; drug-delivery nanosystems; skin cancer; skin penetration; vismodegib; zebrafish

Year:  2021        PMID: 33535434      PMCID: PMC7912039          DOI: 10.3390/pharmaceutics13020186

Source DB:  PubMed          Journal:  Pharmaceutics        ISSN: 1999-4923            Impact factor:   6.321


  53 in total

1.  Avoiding failed reconstitution of ultradeformable liposomes upon dehydration.

Authors:  J Montanari; D I Roncaglia; L A Lado; M J Morilla; E L Romero
Journal:  Int J Pharm       Date:  2009-01-21       Impact factor: 5.875

2.  A glucose-targeted mixed micellar formulation outperforms Genexol in breast cancer cells.

Authors:  Marcela A Moretton; Ezequiel Bernabeu; Estefanía Grotz; Lorena Gonzalez; Marcela Zubillaga; Diego A Chiappetta
Journal:  Eur J Pharm Biopharm       Date:  2017-02-10       Impact factor: 5.571

3.  Polymeric micelle nanocarriers for targeted epidermal delivery of the hedgehog pathway inhibitor vismodegib: formulation development and cutaneous biodistribution in human skin.

Authors:  Somnath G Kandekar; Mayank Singhal; Kiran B Sonaje; Yogeshvar N Kalia
Journal:  Expert Opin Drug Deliv       Date:  2019-04-26       Impact factor: 6.648

4.  Effect of size, surface charge, and hydrophobicity of poly(amidoamine) dendrimers on their skin penetration.

Authors:  Yang Yang; Suhair Sunoqrot; Chelsea Stowell; Jingli Ji; Chan-Woo Lee; Jin Woong Kim; Seema A Khan; Seungpyo Hong
Journal:  Biomacromolecules       Date:  2012-06-05       Impact factor: 6.988

5.  Vesicles as a tool for transdermal and dermal delivery.

Authors:  P Loan Honeywell-Nguyen; Joke A Bouwstra
Journal:  Drug Discov Today Technol       Date:  2005

6.  Novel Soluplus(®)-TPGS mixed micelles for encapsulation of paclitaxel with enhanced in vitro cytotoxicity on breast and ovarian cancer cell lines.

Authors:  Ezequiel Bernabeu; Lorena Gonzalez; Maximiliano Cagel; Esteban P Gergic; Marcela A Moretton; Diego A Chiappetta
Journal:  Colloids Surf B Biointerfaces       Date:  2016-01-07       Impact factor: 5.268

7.  Ethosomes for skin delivery of ammonium glycyrrhizinate: in vitro percutaneous permeation through human skin and in vivo anti-inflammatory activity on human volunteers.

Authors:  Donatella Paolino; Giuseppe Lucania; Domenico Mardente; Franco Alhaique; Massimo Fresta
Journal:  J Control Release       Date:  2005-08-18       Impact factor: 9.776

8.  Ethosomes - novel vesicular carriers for enhanced delivery: characterization and skin penetration properties.

Authors:  E Touitou; N Dayan; L Bergelson; B Godin; M Eliaz
Journal:  J Control Release       Date:  2000-04-03       Impact factor: 9.776

9.  Sulforaphane-Loaded Ultradeformable Vesicles as A Potential Natural Nanomedicine for the Treatment of Skin Cancer Diseases.

Authors:  Maria Chiara Cristiano; Francesca Froiio; Roberta Spaccapelo; Antonia Mancuso; Steven P Nisticò; Betty P Udongo; Massimo Fresta; Donatella Paolino
Journal:  Pharmaceutics       Date:  2019-12-19       Impact factor: 6.321

View more
  1 in total

1.  Enhancing the Bioavailability and Efficacy of Vismodegib for the Control of Skin Cancer: In Vitro and In Vivo Studies.

Authors:  Heba F Salem; Amr Gamal; Haitham Saeed; Marwa Kamal; Alaa S Tulbah
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.